Continuing advances in cell and gene therapy (CGT) are transforming how biopharma companies treat and potentially cure certain diseases. Browse our collection of articles for an in-depth look at the opportunities, challenges, and implications for stakeho
通过参考Adriana G Lopes 等人发表于 Cell&Gene Therapy Insights 的《Cost analysis of vein-to-vein CAR T-cell therapy: automated manufacturing and supply chain》。 ASGCT 和ARM的季度/半 年度报告以及业内各公司财报,我们对 CAR-T 大规模生产(5000 人份)情景下的各流程 成本进行了拆分。 根据我们估算,大...
Advanced therapy medicinal products (ATMPs) have the potential to transform medicine, with the promise to treat, manage and cure some of the most severe diseases. However, the development of ATMPs is complex and successful transition from preclinical research to the approved clinical product faces a...
Our cell and gene therapy expertise covers a wide range of modalities, including autologous and allogeneic T-cell therapies (CAR-T, TCR, Treg), NK cells, Viral Vectors (LVV, AAV, Adeno, Oncolytic) iPSCs, HSCs, MSCs, Exosome (Extracellular vesicle)-based therapies, Dendritic cells and more...
Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside Recombinant adeno-associated viruses (rAAVs) have emerged as an attractive tool for gene delivery, and demonstrated tremendous promise in gene therapy and gene editing—therapeutic modalities with potent...
Cell and Gene Therapy Experts Medpace’s team of Medical Directors, Advanced Clinical Practitioners, and Clinical Trial Managers have led advancements in the field across tens of cell and gene therapy studies in the U.S., Europe, and Asia Pacific. The deep experience has given Medpace a robust...
to enter the market through JV partnerships (Fosun/Kite), while certain biological regimens, such as Biogen’s Spinraza (a nucleotide drug that controls mRNA splicing and the expression of survival motor neuron protein), are classified as a conventional biologic product rather than g...
cell and gene therapy investment cell therapy fundraising trends gene therapy key investment drivers Introduction The International Society for Cell and Gene Therapy (ISCT) is a global professional society dedicated to the translational development of cell and gene therapies (CGTs) for patients with sig...
Many biopharma companies are investing in cell and gene therapy, albeit cautiously, amid a nascent market. Here are investment opportunities and entry strategies.
Although diabetes results in part from a deficiency of normal pancreatic beta cells, inducing human beta cells to regenerate is difficult. Reasoning that insulinomas hold the “genomic recipe” for beta cell expansion, we surveyed 38 human insulinomas to obtain insights into therapeutic pathways for ...